Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,787 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MAJOR DEPRESSIVE DISORDER Clear all
Not listed Not applicable Interventional

Patient-Centered Depression Care for African Americans

NCT00243425
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Standard Quality Improvement, Patient-centered Intervention
Procedure
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
Wilmington, Delaware • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2005 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 4 Interventional

Study of Medication and Placebo Response in Major Depression

NCT00229476
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
sertraline (Zoloft)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Not applicable Interventional

Telephone Care as a Substitute for Routine Psychiatric Medication

NCT00105885
View directory record Official record
Conditions
Major Depression, Posttraumatic Stress Disorders, Anxiety Disorders
Interventions
telephone care
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

NCT02288325
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Repeated Neurocognitive Measurements in Depressed Patients

NCT04916548
View directory record Official record
Conditions
Depression, Unipolar
Interventions
Intravenous Ketamine
Drug
Lead sponsor
Rebecca Price
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 4 Interventional

Sleep Deprivation Plus Paroxetine for Treating Major Depression in Elderly Individuals

NCT00178035
View directory record Official record
Conditions
Depression
Interventions
paroxetine, One night of Total Sleep Deprivation
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of ORG 34517 for Major Depression With Psychotic Features

NCT00226278
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
ORG 34517
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 4 Interventional

Oliceridine in Patients With Acute Burn Injuries

NCT05465226
View directory record Official record
Conditions
Acute Pain, Burns, Adverse Drug Event, Respiratory Depression, Nausea and Vomiting, Postoperative
Interventions
Oliceridine, Historical opioid use
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

NCT02600507
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lumateperone (ITI-007), Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
42
States / cities
Rogers, Arkansas • Cerritos, California • Costa Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 8, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01361555
View directory record Official record
Conditions
Depression
Interventions
Placebo matching with BMS-820836, BMS-820836
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
94
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 8, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional Results available

Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

NCT02660528
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tocilizumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 8, 2026, 10:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Behavioral Processes Underlying Reward Processing in Depression

NCT00205933
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Affective Neuroscience Laboratory
Other
Eligibility
18 Years to 64 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability

NCT01464229
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Iloperidone, Placebo
Drug
Lead sponsor
Maurizio Fava, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Novel Neural Circuit Biomarkers of Major Depression Response to CCBT

NCT03096886
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Depressive Disorder, Depression, Unipolar
Interventions
Computer-Augmented Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 8, 2026, 10:58 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Internet Intervention for the Prevention of Depression - Approaches to Improving Mood

NCT01080105
View directory record Official record
Conditions
Individuals at Risk for Depression
Interventions
AIM Web based intervention + surveillance, AIM web based intervention, Educational website
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
19 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 8, 2026, 10:58 PM EDT
Enrolling by invitation Phase 3 Interventional

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

NCT06605105
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003
Drug
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
42
States / cities
Phoenix, Arizona • Glendale, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

NCT05385783
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003, Psychotherapy, Placebo, Psychological Support
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Activation + Cognitive Processing Therapy for PTSD and Comorbid MDD

NCT02874131
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Major Depressive Disorder
Interventions
Behavioral Activation, Cognitive Processing Therapy
Behavioral
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 8, 2026, 10:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Conte Center for the Neuroscience of Depression in Late Life

NCT00576875
View directory record Official record
Conditions
Major Depression
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 8, 2026, 10:58 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT07196501
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1065845, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Oceanside, California • Orange, California • San Jose, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

NCT04352101
View directory record Official record
Conditions
Major Depression
Interventions
Bupropion XL, Escitalopram
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 2 Interventional

AZD6765 Severe Major Depressive Disorder (MDD) IV

NCT00781742
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Esketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 8, 2026, 10:58 PM EDT
Completed Not applicable Interventional

Cognitive Training for Mood and Anxiety Disorders

NCT02256566
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Bipolar Disorder, Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Social Phobia
Interventions
emotional memory training exercise, memory training exercise
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 8, 2026, 10:58 PM EDT